Top Page
Atomo Diagnostics Ltd.
(Sydney:AT1)
Atomo Diagnostics Ltd. (AT1) vs. iShares MSCI Australia ETF (EWA)
Atomo Diagnostics Ltd. Business Overview & Revenue Model
Atomo Diagnostics Ltd. Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.22M | 4.09M | 2.54M | 12.34M | 6.72M | 5.37M |
| Gross Profit | 1.48M | 1.44M | -6.08M | -1.85M | -1.71M | -464.83K |
| EBITDA | -4.95M | -5.42M | -9.25M | -4.72M | -4.70M | -4.05M |
| Net Income | -6.45M | -6.85M | -9.96M | -5.71M | -6.02M | -9.22M |
Balance Sheet | ||||||
| Total Assets | 9.25M | 11.38M | 16.47M | 26.62M | 32.24M | 36.10M |
| Cash, Cash Equivalents and Short-Term Investments | 2.90M | 3.69M | 6.47M | 12.97M | 17.95M | 27.10M |
| Total Debt | 199.38K | 84.67K | 254.88K | 340.81K | 67.59K | 55.54K |
| Total Liabilities | 1.84M | 1.29M | 1.68M | 1.81M | 2.15M | 1.62M |
| Stockholders Equity | 7.41M | 10.08M | 14.79M | 24.81M | 30.09M | 34.48M |
Cash Flow | ||||||
| Free Cash Flow | -3.59M | -4.70M | -6.25M | -5.11M | -10.12M | -8.26M |
| Operating Cash Flow | -3.53M | -4.69M | -5.85M | -2.81M | -4.23M | -6.26M |
| Investing Cash Flow | -54.49K | -16.08K | -401.28K | -2.31M | -5.90M | -1.99M |
| Financing Cash Flow | -191.39K | 1.87M | -170.75K | 17.61K | 997.37K | 33.61M |
Atomo Diagnostics Ltd. Technical Analysis
Atomo Diagnostics Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | AU$57.26B | 28.46 | 25.23% | 1.30% | 10.54% | 38.69% | |
73 Outperform | $1.25B | 75.64 | 9.23% | ― | 10.79% | 5.20% | |
69 Neutral | $113.47B | 27.23 | 15.38% | 1.77% | 8.00% | 9.09% | |
69 Neutral | AU$8.27B | 161.85 | 14.52% | ― | 55.85% | 893.42% | |
52 Neutral | AU$266.90M | ― | -0.87% | 7.59% | 14.24% | -109.59% | |
51 Neutral | $7.41B | 0.36 | -61.88% | 2.33% | 16.99% | 1.69% | |
43 Neutral | AU$11.06M | ― | -61.15% | ― | 35.63% | 18.55% |
Atomo Diagnostics Ltd. Corporate Events
Atomo Diagnostics Limited has issued 36,259,457 fully paid ordinary shares to new and existing investors, including a Director, at an issue price of $0.0185 per share, as part of a previously announced plan. Additionally, the company issued 14,723,685 shares under a Share Purchase Plan. This move is part of Atomo’s strategy to strengthen its financial position and support its operations in the competitive diagnostic market, potentially impacting its market positioning and stakeholder interests.
Atomo Diagnostics Ltd. has announced the quotation of 50,983,142 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code AT1, effective June 27, 2025. This move is part of a previously announced transaction and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the accessibility of its shares.
Atomo Diagnostics Limited has successfully completed its Share Purchase Plan (SPP), raising $272,387.50 through applications for 14,723,685 shares, with an additional Tranche 2 Placement approved to raise $1,257,800. This fundraising initiative strengthens the company’s financial position, enabling it to advance its operational activities and maintain its competitive edge in the global diagnostic market.
Atomo Diagnostics Ltd. announced the results of its Extraordinary General Meeting, where all proposed resolutions were passed. The meeting included approvals for the issuance of shares and options as part of various placements and share purchase plans, indicating a strategic move to strengthen the company’s financial position and expand its shareholder base. This development is likely to enhance Atomo’s operational capabilities and market presence, benefiting stakeholders by potentially increasing the company’s growth prospects.
Atomo Diagnostics Limited has secured a significant order worth approximately $450,000 from the National Association of People with HIV Australia (NAPWHA) for HIV Self-Tests. This order is part of a government-funded initiative to increase HIV testing rates among high-risk groups, facilitated by partnerships with organizations like Grindr. The expansion of the program highlights the growing demand for at-home sexual health testing, reflecting a broader public health strategy to manage HIV more effectively.
Atomo Diagnostics Ltd. has announced an Extraordinary General Meeting of Shareholders scheduled for June 23, 2025, at its headquarters in Leichhardt, Australia. The company has transitioned to electronic dissemination of meeting materials in accordance with recent legislative changes, emphasizing the importance of shareholders lodging proxies in advance. This shift to digital communication reflects Atomo’s commitment to modernizing its shareholder engagement and aligns with broader industry trends towards sustainability and efficiency.
Atomo Diagnostics Limited has appointed its current CEO and Managing Director, Mr. John Kelly, as the Interim Chair of the Board following recent changes in the Board’s composition. This move is intended to maintain continuity and stability in the company’s leadership. The Board is committed to strong corporate governance and plans to appoint a permanent independent Chair in the future. Mr. Kelly’s remuneration will remain unchanged, and shareholders will be kept informed of further updates.
Atomo Diagnostics Ltd. has announced the opening of its Share Purchase Plan (SPP Offer), allowing eligible shareholders to acquire shares at a discounted price. The plan aims to raise up to $1,000,000, with the possibility of increasing the maximum based on demand. Participants will receive one free attaching option for each share subscribed, with the offer closing on June 23, 2025. This initiative is part of Atomo’s strategy to strengthen its financial position and support its ongoing operations in the global diagnostic market.
Atomo Diagnostics Ltd. has announced a target market determination for its new Options offering under a prospectus dated May 20, 2025. The company aims to raise up to $1 million through a security purchase plan and offers additional options to cover any shortfall. The initiative is designed for investors seeking exposure to equities in the healthcare sector, with a short to medium-term investment outlook. The Options allow investors to potentially increase their shareholding in the company, although there are no guarantees of income or capital protection.
Atomo Diagnostics Ltd. has announced a prospectus offering up to 54,054,054 shares at $0.0185 per share, along with unlisted options, to raise up to $1,000,000 through a security purchase plan. The offering is subject to shareholder approval and aims to address any shortfalls by offering additional shares and options. The securities are considered highly speculative, and investors are advised to consult professional advisors due to the associated risks.
Atomo Diagnostics Ltd. has announced a change in the substantial holding of its voting shares. GZ Family Holdings Pty Ltd and GZ Super Investments Pty Ltd have increased their voting power in Atomo Diagnostics, indicating a strategic consolidation of control. This change reflects a significant shift in the company’s shareholder structure, potentially impacting its governance and strategic direction.
Atomo Diagnostics Limited announced the resignation of Paul Kasian from its board of directors, effective May 2, 2025. This change in leadership may influence the company’s strategic direction and stakeholder relations, as Kasian held significant shares through Yongala Investments Pty Ltd, indicating his substantial involvement in the company’s operations.
Atomo Diagnostics Ltd. has announced the appointment of Anthony May as a director, effective from May 2, 2025. This appointment is part of the company’s ongoing efforts to strengthen its leadership team, which could impact its strategic direction and operational effectiveness in the diagnostics industry.
Atomo Diagnostics Limited announced the issuance of 46,929,731 fully paid ordinary shares to new and existing investors at an issue price of $0.0185 per share. This move, executed without disclosure under the Corporations Act, aims to strengthen the company’s financial position and support its operations in the competitive global diagnostic market. The announcement confirms Atomo’s compliance with relevant legal provisions and assures stakeholders of its transparency and adherence to regulatory standards.
Atomo Diagnostics Ltd. has announced the quotation of 46,929,731 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 5, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing opportunities for stakeholders to engage with its growth strategy.
Atomo Diagnostics Ltd. has updated its previous announcement regarding the issuance of securities, specifically adjusting the number of securities to be issued in Tranche 1 and Tranche 2 of the placement. This adjustment is crucial for stakeholders as it corrects the total amount of securities being issued, impacting the company’s financial strategy and market positioning.
Atomo Diagnostics Ltd. has reported significant growth in its HIV Self-Test business, highlighted by a $230k order for the national scale-up of the CONNECT Programme in Australia and a product launch in New Zealand through Chemist Warehouse. The company also secured an exclusive license for a novel syphilis test, supported by a $2.44 million grant from the Commonwealth Government, which will aid in further analytical testing and commercial discussions.
Atomo Diagnostics Ltd. announced a proposed issue of securities through a securities purchase plan and a placement, aiming to issue a total of 166,486,487 new securities. This move is expected to enhance the company’s capital structure, potentially strengthening its market position and providing additional resources to support its operational and strategic initiatives.
Atomo Diagnostics Limited has successfully completed a capital raise of up to $3.1 million through a share placement and share purchase plan, supported by existing shareholders. This capital raise aims to support the company’s general working capital needs and involves issuing new shares and options, with a board restructure and operational review expected to result in further cost savings and strategic alignment.
Atomo Diagnostics Limited announced that it will release its Q3 FY25 results on April 24, 2025, with a briefing webinar scheduled for April 30, 2025. This announcement is part of Atomo’s ongoing efforts to engage with analysts and investors, reflecting its commitment to transparency and stakeholder communication. The release of these results and the subsequent webinar could provide insights into the company’s financial health and strategic direction, potentially impacting its market positioning and stakeholder confidence.
Atomo Diagnostics Ltd. has announced a change in the director’s interest, specifically involving John Kelly, who is a controller of Dalraida Holdings Pty Ltd. The change involved the expiry of 666,666 unquoted options without exercise as of April 14, 2025. This adjustment in the director’s interest does not involve any acquisition or disposal of shares, indicating a neutral impact on the company’s operations and market positioning.
Atomo Diagnostics Limited has requested a trading halt on its securities on the Australian Securities Exchange, pending a significant announcement related to a capital raising initiative. This move is aimed at managing the company’s continuous disclosure obligations and is expected to impact the company’s financial strategy and market positioning.
Atomo Diagnostics announced the national expansion of the CONNECT Programme, which will provide free HIV self-tests through vending machines across Australia, funded by the Federal Government. This initiative, supported by an initial order from Thorne Harbour Health, represents a significant advancement in public health efforts to increase access to HIV self-testing. Additionally, Atomo has launched its HIV Self-Test in New Zealand through Chemist Warehouse, marking its entry into the country’s largest retail pharmacy chain. These developments highlight Atomo’s growing influence in the HIV testing market and its commitment to expanding international market access.